LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company
dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases,
today announced that as of today the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI).
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock
Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry
Classification Benchmark (ICB).
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund. All securities in the NASDAQ
Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and
share volume requirements among other criteria.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based
on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to
management only as of the date of this press release. Our actual results could differ materially from those anticipated in these
forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our
filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given
these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as
required by law.
ProQR Therapeutics N.V.
Investor Contact:
Lisa Hayes
Vice President of Investor Relations and Corporate Communications
T: +1 202 360 4855
ir@proqr.com
Media Contact:
Sara Zelkovic
LifeSci Public Relations
T: +1 646 876 4933
Sara@lifescipublicrelations.com
